Report Detail
Global Parkinsons Disease Drugs Market Insights, Forecast to 2025
- RnM2676619 |
- 14 June, 2019 |
- Global |
- 110 Pages |
- QYResearch |
- Pharma & Healthcare
Parkinson's disease (PD) is a long-term degenerative disorder of the central nervous system that mainly affects the motor system.The symptoms generally come on slowly over time.Early in the disease, the most obvious are shaking, rigidity, slowness of movement, and difficulty with walking.Thinking and behavioral problems may also occur.Dementia becomes common in the advanced stages of the disease.Depression and anxiety are also common, occurring in more than a third of people with PD.Other symptoms include sensory, sleep, and emotional problems.The main motor symptoms are collectively called "parkinsonism", or a "parkinsonian syndrome"
The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World. Annual estimates and forecasts are provided for the period 2018 through 2025. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.
This report analyzes the worldwide markets for Parkinsons Disease Drugs in US$ by following Product Segments.: Clinical, Experiment
Company profiles are primarily based on public domain information including company
Johnson & Johnson
Gilead Sciences
Pacira
Sun Pharmaceutical
Luye Pharma
Sigma-Tau Group
Fudan-Zhangjiang
Teva Pharmaceutical
CSPC
Novartis
Kingond Pharm
The global Parkinsons Disease Drugs market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Parkinsons Disease Drugs market based on company, product type, end user and key regions.
This report studies the global market size of Parkinsons Disease Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Parkinsons Disease Drugs in these regions.
This research report categorizes the global Parkinsons Disease Drugs market by top players/brands, region, type and end user. This report also studies the global Parkinsons Disease Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Johnson & Johnson
Gilead Sciences
Pacira
Sun Pharmaceutical
Luye Pharma
Sigma-Tau Group
Fudan-Zhangjiang
Teva Pharmaceutical
CSPC
Novartis
Kingond Pharm
Market size by Product
Clinical
Experiment
Market size by End User
Treament
Prevention
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Parkinsons Disease Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Parkinsons Disease Drugs market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Parkinsons Disease Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Parkinsons Disease Drugs submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Parkinsons Disease Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Parkinsons Disease Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
- 1.1 Parkinsons Disease Drugs Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Parkinsons Disease Drugs Market Size Growth Rate by Product
- 1.4.2 Clinical
- 1.4.3 Experiment
- 1.5 Market by End User
- 1.5.1 Global Parkinsons Disease Drugs Market Size Growth Rate by End User
- 1.5.2 Treament
- 1.5.3 Prevention
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Parkinsons Disease Drugs Market Size
- 2.1.1 Global Parkinsons Disease Drugs Revenue 2014-2025
- 2.1.2 Global Parkinsons Disease Drugs Sales 2014-2025
- 2.2 Parkinsons Disease Drugs Growth Rate by Regions
- 2.2.1 Global Parkinsons Disease Drugs Sales by Regions
- 2.2.2 Global Parkinsons Disease Drugs Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Parkinsons Disease Drugs Sales by Manufacturers
- 3.1.1 Parkinsons Disease Drugs Sales by Manufacturers
- 3.1.2 Parkinsons Disease Drugs Sales Market Share by Manufacturers
- 3.1.3 Global Parkinsons Disease Drugs Market Concentration Ratio (CR5 and HHI)
- 3.2 Parkinsons Disease Drugs Revenue by Manufacturers
- 3.2.1 Parkinsons Disease Drugs Revenue by Manufacturers (2014-2019)
- 3.2.2 Parkinsons Disease Drugs Revenue Share by Manufacturers (2014-2019)
- 3.3 Parkinsons Disease Drugs Price by Manufacturers
- 3.4 Parkinsons Disease Drugs Manufacturing Base Distribution, Product Types
- 3.4.1 Parkinsons Disease Drugs Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Parkinsons Disease Drugs Product Type
- 3.4.3 Date of International Manufacturers Enter into Parkinsons Disease Drugs Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Parkinsons Disease Drugs Sales by Product
- 4.2 Global Parkinsons Disease Drugs Revenue by Product
- 4.3 Parkinsons Disease Drugs Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Parkinsons Disease Drugs Breakdown Data by End User
6 North America
- 6.1 North America Parkinsons Disease Drugs by Countries
- 6.1.1 North America Parkinsons Disease Drugs Sales by Countries
- 6.1.2 North America Parkinsons Disease Drugs Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Parkinsons Disease Drugs by Product
- 6.3 North America Parkinsons Disease Drugs by End User
7 Europe
- 7.1 Europe Parkinsons Disease Drugs by Countries
- 7.1.1 Europe Parkinsons Disease Drugs Sales by Countries
- 7.1.2 Europe Parkinsons Disease Drugs Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Parkinsons Disease Drugs by Product
- 7.3 Europe Parkinsons Disease Drugs by End User
8 Asia Pacific
- 8.1 Asia Pacific Parkinsons Disease Drugs by Countries
- 8.1.1 Asia Pacific Parkinsons Disease Drugs Sales by Countries
- 8.1.2 Asia Pacific Parkinsons Disease Drugs Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Parkinsons Disease Drugs by Product
- 8.3 Asia Pacific Parkinsons Disease Drugs by End User
9 Central & South America
- 9.1 Central & South America Parkinsons Disease Drugs by Countries
- 9.1.1 Central & South America Parkinsons Disease Drugs Sales by Countries
- 9.1.2 Central & South America Parkinsons Disease Drugs Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Parkinsons Disease Drugs by Product
- 9.3 Central & South America Parkinsons Disease Drugs by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Parkinsons Disease Drugs by Countries
- 10.1.1 Middle East and Africa Parkinsons Disease Drugs Sales by Countries
- 10.1.2 Middle East and Africa Parkinsons Disease Drugs Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Parkinsons Disease Drugs by Product
- 10.3 Middle East and Africa Parkinsons Disease Drugs by End User
11 Company Profiles
- 11.1 Johnson & Johnson
- 11.1.1 Johnson & Johnson Company Details
- 11.1.2 Company Business Overview
- 11.1.3 Johnson & Johnson Parkinsons Disease Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 Johnson & Johnson Parkinsons Disease Drugs Products Offered
- 11.1.5 Johnson & Johnson Recent Development
- 11.2 Gilead Sciences
- 11.2.1 Gilead Sciences Company Details
- 11.2.2 Company Business Overview
- 11.2.3 Gilead Sciences Parkinsons Disease Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 Gilead Sciences Parkinsons Disease Drugs Products Offered
- 11.2.5 Gilead Sciences Recent Development
- 11.3 Pacira
- 11.3.1 Pacira Company Details
- 11.3.2 Company Business Overview
- 11.3.3 Pacira Parkinsons Disease Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 Pacira Parkinsons Disease Drugs Products Offered
- 11.3.5 Pacira Recent Development
- 11.4 Sun Pharmaceutical
- 11.4.1 Sun Pharmaceutical Company Details
- 11.4.2 Company Business Overview
- 11.4.3 Sun Pharmaceutical Parkinsons Disease Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 Sun Pharmaceutical Parkinsons Disease Drugs Products Offered
- 11.4.5 Sun Pharmaceutical Recent Development
- 11.5 Luye Pharma
- 11.5.1 Luye Pharma Company Details
- 11.5.2 Company Business Overview
- 11.5.3 Luye Pharma Parkinsons Disease Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 Luye Pharma Parkinsons Disease Drugs Products Offered
- 11.5.5 Luye Pharma Recent Development
- 11.6 Sigma-Tau Group
- 11.6.1 Sigma-Tau Group Company Details
- 11.6.2 Company Business Overview
- 11.6.3 Sigma-Tau Group Parkinsons Disease Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 Sigma-Tau Group Parkinsons Disease Drugs Products Offered
- 11.6.5 Sigma-Tau Group Recent Development
- 11.7 Fudan-Zhangjiang
- 11.7.1 Fudan-Zhangjiang Company Details
- 11.7.2 Company Business Overview
- 11.7.3 Fudan-Zhangjiang Parkinsons Disease Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.7.4 Fudan-Zhangjiang Parkinsons Disease Drugs Products Offered
- 11.7.5 Fudan-Zhangjiang Recent Development
- 11.8 Teva Pharmaceutical
- 11.8.1 Teva Pharmaceutical Company Details
- 11.8.2 Company Business Overview
- 11.8.3 Teva Pharmaceutical Parkinsons Disease Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.8.4 Teva Pharmaceutical Parkinsons Disease Drugs Products Offered
- 11.8.5 Teva Pharmaceutical Recent Development
- 11.9 CSPC
- 11.9.1 CSPC Company Details
- 11.9.2 Company Business Overview
- 11.9.3 CSPC Parkinsons Disease Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.9.4 CSPC Parkinsons Disease Drugs Products Offered
- 11.9.5 CSPC Recent Development
- 11.10 Novartis
- 11.10.1 Novartis Company Details
- 11.10.2 Company Business Overview
- 11.10.3 Novartis Parkinsons Disease Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.10.4 Novartis Parkinsons Disease Drugs Products Offered
- 11.10.5 Novartis Recent Development
- 11.11 Kingond Pharm
12 Future Forecast
- 12.1 Parkinsons Disease Drugs Market Forecast by Regions
- 12.1.1 Global Parkinsons Disease Drugs Sales Forecast by Regions 2019-2025
- 12.1.2 Global Parkinsons Disease Drugs Revenue Forecast by Regions 2019-2025
- 12.2 Parkinsons Disease Drugs Market Forecast by Product
- 12.2.1 Global Parkinsons Disease Drugs Sales Forecast by Product 2019-2025
- 12.2.2 Global Parkinsons Disease Drugs Revenue Forecast by Product 2019-2025
- 12.3 Parkinsons Disease Drugs Market Forecast by End User
- 12.4 North America Parkinsons Disease Drugs Forecast
- 12.5 Europe Parkinsons Disease Drugs Forecast
- 12.6 Asia Pacific Parkinsons Disease Drugs Forecast
- 12.7 Central & South America Parkinsons Disease Drugs Forecast
- 12.8 Middle East and Africa Parkinsons Disease Drugs Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Parkinsons Disease Drugs Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on Parkinsons Disease Drugs. Industry analysis & Market Report on Parkinsons Disease Drugs is a syndicated market report, published as Global Parkinsons Disease Drugs Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Parkinsons Disease Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
